QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial
Positive News SentimentPositive News
NASDAQ:PRVB

Provention Bio (PRVB) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free PRVB Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$24.98
▼
$25.00
50-Day Range
$23.74
▼
$24.98
52-Week Range
$3.18
▼
$25.00
Volume
9.12 million shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
PRVB stock logo

About Provention Bio Stock (NASDAQ:PRVB)

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

PRVB Stock News Headlines

December 29, 2023 | morningstar.com
Macrogenics Inc MGNX
May 1, 2023 | finance.yahoo.com
Sanofi/Provention: innovative diabetes drug is a good fit
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 29, 2023 | finance.yahoo.com
Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%
April 28, 2023 | seekingalpha.com
Sanofi completes Provention Bio acquisition
April 27, 2023 | finance.yahoo.com
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline
April 27, 2023 | finanznachrichten.de
Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
April 26, 2023 | seekingalpha.com
Provention Bio gains after HSR waiting period for Sanofi deal expired
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 26, 2023 | benzinga.com
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
April 22, 2023 | finance.yahoo.com
PRVB Apr 2023 23.000 put
April 11, 2023 | msn.com
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
April 2, 2023 | finance.yahoo.com
Provention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimates
March 27, 2023 | bizjournals.com
Gaithersburg’s Novavax locks in consulting deal with outgoing R&D head
March 17, 2023 | benzinga.com
(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?
March 16, 2023 | finance.yahoo.com
Q4 2022 MacroGenics Inc Earnings Call
March 15, 2023 | benzinga.com
Provention Bio's Earnings Outlook
March 14, 2023 | msn.com
SMBC Nikko Downgrades Provention Bio (PRVB)
March 14, 2023 | msn.com
Jefferies Downgrades Provention Bio (PRVB)
March 14, 2023 | proactiveinvestors.com
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
March 14, 2023 | benzinga.com
Short Volatility Alert: Provention Bio Inc
March 14, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About Provention Bio
March 13, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
March 13, 2023 | finance.yahoo.com
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
March 13, 2023 | msn.com
Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug
March 13, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. Buyout
March 13, 2023 | businesswire.com
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
CUSIP
N/A
CIK
1695357
Web
www.proventionbio.com
Phone
(908) 428-9136
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%
Return on Equity
-103.36%
Return on Assets
-69.08%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.93
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$12.90 million
Price / Sales
183.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
17.84

Miscellaneous

Outstanding Shares
94,780,000
Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

PRVB Stock Analysis - Frequently Asked Questions

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company earned $0.68 million during the quarter, compared to analysts' expectations of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%. During the same period in the prior year, the company earned ($0.56) EPS.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

This page (NASDAQ:PRVB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press